AVAX Technologies, Inc. (AVXT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2007 | -5.9 Million USD | -425.92% |
| 2006 | -1.12 Million USD | 78.61% |
| 2005 | -5.24 Million USD | -342.38% |
| 2004 | -1.18 Million USD | -2178.89% |
| 2003 | 57.06 Thousand USD | 101.59% |
| 2002 | -3.59 Million USD | 68.49% |
| 2001 | -11.4 Million USD | -230.8% |
| 2000 | -3.44 Million USD | -1.37% |
| 1999 | -3.4 Million USD | -1033.33% |
| 1998 | -300 Thousand USD | 95.59% |
| 1997 | -6.8 Million USD | 50.72% |
| 1996 | -13.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2008 Q1 | -3.26 Million USD | 44.73% |
| 2008 Q2 | -1.34 Million USD | 58.74% |
| 2008 Q3 | -344.94 Thousand USD | 74.38% |
| 2007 Q3 | -7.68 Million USD | 9.75% |
| 2007 Q1 | -554.13 Thousand USD | 50.63% |
| 2007 Q2 | -8.51 Million USD | -1436.47% |
| 2007 FY | -5.9 Million USD | -425.92% |
| 2007 Q4 | -5.9 Million USD | 23.17% |
| 2006 Q2 | -3.57 Million USD | 21.74% |
| 2006 Q3 | -2.09 Million USD | 41.42% |
| 2006 FY | -1.12 Million USD | 78.61% |
| 2006 Q4 | -1.12 Million USD | 46.46% |
| 2006 Q1 | -4.57 Million USD | 12.87% |
| 2005 Q4 | -5.24 Million USD | 19.18% |
| 2005 Q1 | -2.39 Million USD | -101.94% |
| 2005 Q2 | -7.72 Million USD | -222.33% |
| 2005 FY | -5.24 Million USD | -342.38% |
| 2005 Q3 | -6.49 Million USD | 15.91% |
| 2004 FY | -1.18 Million USD | -2178.89% |
| 2004 Q4 | -1.18 Million USD | 28.95% |
| 2004 Q1 | 590.06 Thousand USD | 933.98% |
| 2004 Q2 | -2.56 Million USD | -535.43% |
| 2004 Q3 | -1.66 Million USD | 35.01% |
| 2003 Q4 | 57.06 Thousand USD | 113.2% |
| 2003 Q1 | -1.31 Million USD | 63.42% |
| 2003 FY | 57.06 Thousand USD | 101.59% |
| 2003 Q3 | -432.29 Thousand USD | 30.68% |
| 2003 Q2 | -623.62 Thousand USD | 52.54% |
| 2002 Q3 | -5.31 Million USD | 27.35% |
| 2002 Q1 | -9.75 Million USD | 14.47% |
| 2002 FY | -3.59 Million USD | 68.49% |
| 2002 Q4 | -3.59 Million USD | 32.35% |
| 2002 Q2 | -7.3 Million USD | 25.04% |
| 2001 FY | -11.4 Million USD | -230.8% |
| 2001 Q4 | -11.4 Million USD | 17.29% |
| 2001 Q1 | -18.41 Million USD | -434.42% |
| 2001 Q3 | -13.78 Million USD | 14.15% |
| 2001 Q2 | -16.05 Million USD | 12.83% |
| 2000 Q4 | -3.44 Million USD | 50.45% |
| 2000 Q2 | -8.03 Million USD | 58.1% |
| 2000 Q3 | -6.95 Million USD | 13.39% |
| 2000 FY | -3.44 Million USD | -1.37% |
| 2000 Q1 | -19.16 Million USD | -463.69% |
| 1999 Q3 | -900 Thousand USD | -12.5% |
| 1999 Q2 | -800 Thousand USD | 61.9% |
| 1999 Q1 | -2.1 Million USD | -600.0% |
| 1999 FY | -3.4 Million USD | -1033.33% |
| 1999 Q4 | -3.4 Million USD | -277.78% |
| 1998 Q1 | -3.4 Million USD | 50.0% |
| 1998 Q2 | -1.8 Million USD | 47.06% |
| 1998 Q3 | -300 Thousand USD | 83.33% |
| 1998 Q4 | -300 Thousand USD | 0.0% |
| 1998 FY | -300 Thousand USD | 95.59% |
| 1997 Q1 | -10.9 Million USD | 0.0% |
| 1997 FY | -6.8 Million USD | 50.72% |
| 1997 Q4 | -6.8 Million USD | 15.0% |
| 1997 Q2 | -9.7 Million USD | 11.01% |
| 1997 Q3 | -8 Million USD | 17.53% |
| 1996 FY | -13.8 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -450526.489% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 204.512% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 113.795% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2264.877% |
| Rebus Holdings, Inc. | 305 Thousand USD | 2035.478% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 6.366% |
| Qrons Inc. | 351.42 Thousand USD | 1779.782% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1048.514% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 113.591% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -28825.946% |
| Skye Bioscience, Inc. | -5.72 Million USD | -3.178% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 137.45% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 243.35% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1569.011% |
| SQZ Biotechnologies Company | -36.23 Million USD | 83.71% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 363.274% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 736.68% |
| Mesoblast Limited | 55.85 Million USD | 110.568% |
| Marizyme, Inc. | 18.56 Million USD | 131.791% |
| Genus plc | 190.6 Million USD | 103.097% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 364.027% |
| Pharming Group N.V. | 109.8 Million USD | 105.376% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 786.227% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 586.306% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 968.119% |
| ContraFect Corporation | -6.02 Million USD | 2.038% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4484.47% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 610.91% |
| IMV Inc. | 7.67 Million USD | 176.96% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 207.294% |
| MultiCell Technologies, Inc. | 90.04 USD | 6556305.02% |
| ONE Bio Corp. | 9.04 Million USD | 165.301% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -704.276% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 145.599% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 531.53% |
| Q BioMed Inc. | 4.06 Million USD | 245.399% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 119.321% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 685.801% |
| Biomind Labs Inc. | 711.4 Thousand USD | 929.799% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 109.75% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 395.25% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 146.095% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1741.102% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4322.488% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 29813.631% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 368.086% |
| GB Sciences, Inc. | 1.74 Million USD | 437.844% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -3111.965% |
| HST Global, Inc. | 96.79 Thousand USD | 6198.795% |
| CSL Limited | 10.52 Billion USD | 100.056% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2962.619% |
| Halberd Corporation | 144.72 Thousand USD | 4179.026% |
| Enzolytics Inc. | 981.65 Thousand USD | 701.352% |
| Agentix Corp. | 37.63 Thousand USD | 15787.085% |
| Resverlogix Corp. | 6.45 Million USD | 191.508% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -777.032% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.709% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 87.443% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 183.485% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 317.942% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 33.221% |
| Zenith Capital Corp. | 10.06 Thousand USD | 58756.667% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.444% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 3045.242% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 347.407% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3688.379% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -32126.264% |
| Kadimastem Ltd | -253.1 Thousand USD | -2232.343% |
| Helix BioMedix, Inc. | -2.57 Million USD | -129.694% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 129.114% |
| BioStem Technologies, Inc. | 4.47 Million USD | 232.003% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 3033.212% |
| LadRx Corporation | -2.03 Million USD | -189.875% |
| Cell Source, Inc. | 9.23 Million USD | 163.943% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1029.394% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1029.394% |
| NovAccess Global Inc. | 2.17 Million USD | 370.98% |
| Affymax, Inc. | -5.59 Million USD | -5.471% |
| Itoco Inc. | 228.3 Thousand USD | 2685.667% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4440.944% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 219.088% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1319.087% |
| CytoDyn Inc. | 20.26 Million USD | 129.134% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -912296.754% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -63592.171% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 176.605% |
| SYBLEU INC | 473.71 Thousand USD | 1346.154% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 232.447% |
| International Stem Cell Corporation | 2.59 Million USD | 327.923% |
| Bioxytran, Inc. | 1.89 Million USD | 410.873% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 9558.297% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 370.678% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 271.905% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 169.019% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 864.063% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -372.257% |
| Neutra Corp. | 52.18 Thousand USD | 11411.643% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -137.172% |
| PureTech Health plc | -167.19 Million USD | 96.469% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2310.377% |
| IXICO plc | -4.44 Million USD | -32.818% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 144.657% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 110.762% |
| CSL Limited | 10.52 Billion USD | 100.056% |
| Cellectis S.A. | -43.81 Million USD | 86.528% |